EP Patent

EP3854385A1 — Methotrexate dosage form

Assigned to Ros Therapeutics Aps · Expires 2021-07-28 · 5y expired

What this patent protects

The present invention relates to a pharmaceutical dosage form comprising an active ingredient such as methotrexate or a pharmaceutically acceptable salt thereof, in particular in the form of pellets, such as multiparticulates, mini-tablets or granulate. It further relates to oral…

USPTO Abstract

The present invention relates to a pharmaceutical dosage form comprising an active ingredient such as methotrexate or a pharmaceutically acceptable salt thereof, in particular in the form of pellets, such as multiparticulates, mini-tablets or granulate. It further relates to oral dosage forms for which saturation kinetics limits the oral use of higher dosages of active ingredients.

Drugs covered by this patent

Patent Metadata

Patent number
EP3854385A1
Jurisdiction
EP
Classification
Expires
2021-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Ros Therapeutics Aps
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.